Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)

Shots:

• The NDA filing is based on P-III SUNBEAM & RADIANCE studies assessing Ozanimod vs Avonex in 1,346 & 1,320 patients with RMS across 21 countries for 12 & 24 mos. respectively
• In H1’19 Celegene has also filed MAA to EMA for relapsing-remitting multiple sclerosis in adults and plans to develop new therapies for RMS in 2020
• Ozanimod (0.92/0.46 mg) is an oral sphingosine 1-phosphate (S1P) receptor modulator and currently in development for other indications including RMS, ulcerative colitis and Crohn’s disease

Click here to read full press release/ article | Ref: Celgene | Image: The Street